Novavax (NVAX) is awaiting the FDA's decision on its COVID-19 vaccine booster, and whether or not the agency will accept the original formula rather than a new variant-specific formula.

However, the company is expecting the FDA to green-light the booster as an option even for those who received other vaccines for their primary or previous booster doses. That's according to chief commercial officer John Trizzino.

While Novamax already received booster approval in other countries, the U.S. remains a slow market for the company. Trizzino said he expects things to pick up when the U.S. market goes commercial, if the public health emergency is declared over sometime next year.

"Frankly, we're looking forward to that, because I think that'll give us more flexibility to communicate and educate about why this is a good vaccine," Trizzino told Yahoo Finance at the World Vaccine Congress Europe in Barcelona.

With doctors making the choices rather than the U.S. government, Novavax has a greater chance of seeing increased administration of its vaccine. To support that, the company is building out regional commercial teams and has grown to a global overall presence of more than 2,000 employees.

"We're now approved in over 43 countries...that doesn't even include emergency listings," Trizzino said.

The U.S. Health and Human Services Department (HHS) just renewed the emergency, indicating it would provide a 60-day notice when it is ready to end the declaration.

Despite the growth and stability the company achieved in the past year, Trizzino believes the investment community is still wary of the company.

"The investment community is not seeing some of these elements," Trizzino said. "And we need to make sure that they understand that we're going to have a significant percentage of the market share. Estimates range from $15 billion of the total COVID market to $30 billion."

Future pipeline

Beyond the COVID-19 vaccines, the company is already looking at broadening its portfolio. A highly anticipated COVID-19 and flu combination vaccine is set to begin Phase 2 trials at the start of 2024, Trizzino said.